Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 26

Sort by

Sort Order Select

Journal Articles

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Cancer Res (2024) 84 (8): 1303–1319.

https://doi.org/10.1158/0008-5472.CAN-23-0438

Published: 15 April 2024

View article titled, ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Includes: Supplementary data

Journal Articles

Abstract IA006: Leveraging the extreme selection induced by therapeutic bottlenecks to subvert resistance via identifying evolutionarily-informed targets for orthogonal immunotherapy

J. Nic Fisk, Katerina Politi, Scott Gettinger, Jeffrey P Townsend

Cancer Res (2024) 84 (3_Supplement_2): IA006.

https://doi.org/10.1158/1538-7445.CANEVOL23-IA006

Published: 01 February 2024

View article titled, Abstract IA006: Leveraging the extreme selection induced by therapeutic bottlenecks to subvert resistance via identifying evolutionarily-informed targets for orthogonal immunotherapy

Journal Articles

PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

Cancer Res (2023) 83 (15): 2513–2526.

https://doi.org/10.1158/0008-5472.CAN-22-3023

Published: 01 August 2023

View article titled, PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

Includes: Supplementary data

Journal Articles

Abstract 451: AICAR targets oncogenic signaling pathways of MUC1-CT

Fareesa Aftab, Alice Rodriguez-Fuguet, Luis Silva, Ikei S. Kobayashi, Jiao Sun, Katerina Politi, Elena Levantini, Wei Zhang, Susumu S. Kobayashi, Wen Cai Zhang

Cancer Res (2023) 83 (7_Supplement): 451.

https://doi.org/10.1158/1538-7445.AM2023-451

Published: 04 April 2023

View article titled, Abstract 451: AICAR targets oncogenic signaling pathways of MUC1-CT

Journal Articles

Abstract NG11: Autologous humanized PDX modeling for immuno-oncology recapitulates the human tumor microenvironment

Cancer Res (2023) 83 (7_Supplement): NG11.

https://doi.org/10.1158/1538-7445.AM2023-NG11

Published: 04 April 2023

View article titled, Abstract NG11: Autologous humanized PDX modeling for immuno-oncology recapitulates the human tumor microenvironment

Journal Articles

Abstract 126: Extreme selection constrains ability of EGFR-driven lung adenocarcinoma to diversify in response to erlotinib therapy

J Nicholas Fisk, Stephen Gaffney, Katerina Politi, Scott Gettinger, Fernando de Miguel, Jeffrey Townsend

Cancer Res (2023) 83 (7_Supplement): 126.

https://doi.org/10.1158/1538-7445.AM2023-126

Published: 04 April 2023

View article titled, Abstract 126: Extreme selection constrains ability of EGFR-driven lung adenocarcinoma to diversify in response to erlotinib therapy

Journal Articles

Abstract 1172: Oncogenic context shapes the fitness landscape of tumor suppression

Cancer Res (2023) 83 (7_Supplement): 1172.

https://doi.org/10.1158/1538-7445.AM2023-1172

Published: 04 April 2023

View article titled, Abstract 1172: Oncogenic context shapes the fitness landscape of tumor suppression

Journal Articles

Abstract 1124: PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells

Cancer Res (2023) 83 (7_Supplement): 1124.

https://doi.org/10.1158/1538-7445.AM2023-1124

Published: 04 April 2023

View article titled, Abstract 1124: PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells

Journal Articles

Abstract 1540: Accumulation of the long noncoding RNA Malat1 is a central driver and therapeutic target in metastatic lung cancer

Elena Martínez-Terroba, Fernando J. de Miguel, Camila Robles-Oteiza, Katerina Politi, Nadya Dimitrova

Cancer Res (2022) 82 (12_Supplement): 1540.

https://doi.org/10.1158/1538-7445.AM2022-1540

Published: 15 June 2022

View article titled, Abstract 1540: Accumulation of the long noncoding RNA Malat1 is a central driver and therapeutic target in metastatic lung cancer

Journal Articles

Abstract 839: YES1 is a novel druggable oncogene in small cell lung cancer

Esther Redin, Eva M. Garrido-Martin, Karmele Valencia, Miriam Redrado, Jose Luis Solorzano, Rafael Carias, Franscisco Exposito, Diego Serrano, Nerea Otegui, Luis Paz Ares, Katerina Politi, Luis M. Montuenga, Alfonso Calvo

Cancer Res (2022) 82 (12_Supplement): 839.

https://doi.org/10.1158/1538-7445.AM2022-839

Published: 15 June 2022

View article titled, Abstract 839: YES1 is a novel druggable oncogene in small cell lung cancer

Journal Articles

Abstract 5848: Inhibition of the CRM1 nuclear export protein can treat mutant KRAS tumors through stabilizing the DLC1 tumor suppressor protein

Brajendra K. Tripathi, Nicole Hirsh, Xiaolan Qian, Dunrui Wang, Marian E. Durkin, Fernando J. de Miguel, Katerina Politi, James H. Doroshow, Douglas R. Lowy

Cancer Res (2022) 82 (12_Supplement): 5848.

https://doi.org/10.1158/1538-7445.AM2022-5848

Published: 15 June 2022

View article titled, Abstract 5848: Inhibition of the CRM1 nuclear export protein can treat mutant KRAS tumors through stabilizing the DLC1 tumor suppressor protein

Journal Articles

Abstract 1572: Broad glutamine pathway inhibition by DRP-104 results in anti-tumor activity in hypermetabolic lung tumors resistant to PD-1 or osimertinib therapy

Morgan Brady, Milica Momcilovic, Chiara Montemurro, Yumi Yokoyama, Heather Christofk, Katerina Politi, Margaret Dugan, Aaron Lisberg, Robert Wild, David B. Shackelford

Cancer Res (2021) 81 (13_Supplement): 1572.

https://doi.org/10.1158/1538-7445.AM2021-1572

Published: 01 July 2021

View article titled, Abstract 1572: Broad glutamine pathway inhibition by DRP-104 results in anti-tumor activity in hypermetabolic lung tumors resistant to PD-1 or osimertinib therapy

Journal Articles

Abstract 2508: Targeting mutant KRAS tumors by inhibiting cytoplasmic EZH2, which directly methylates and destabilizes the DLC1 tumor suppressor protein

Brajendra K. Tripathi, Disha Bhargava, Xiaolan Qian, Dunrui Wang, Marian E. Durkin, Fernando J. de Miguel, Katerina Politi, Kylie J. Walters, James H. Doroshow, Douglas R. Lowy

Cancer Res (2021) 81 (13_Supplement): 2508.

https://doi.org/10.1158/1538-7445.AM2021-2508

Published: 01 July 2021

View article titled, Abstract 2508: Targeting mutant KRAS tumors by inhibiting cytoplasmic EZH2, which directly methylates and destabilizes the DLC1 tumor suppressor protein

Journal Articles

Abstract 1613: A hypoxia-driven transcriptional program characterizes acquired resistance to immune checkpoint inhibitors in lung cancer

Camila Robles-Oteiza, Katherine Hastings, Susan M. Kaech, Katerina Politi

Cancer Res (2021) 81 (13_Supplement): 1613.

https://doi.org/10.1158/1538-7445.AM2021-1613

Published: 01 July 2021

View article titled, Abstract 1613: A hypoxia-driven transcriptional program characterizes acquired resistance to immune checkpoint inhibitors in lung cancer

Journal Articles

Abstract 1094: Genetic determinants of EGFR-driven lung cancer growth and therapeutic response in vivo

Giorgia Foggetti, Chuan Li, Hongchen Cai, Wen-Yang Lin, Deborah Ayeni, Katherine Hastings, Laura Andrejka, Dylan Maghini, Robert Homer, Dmitri A. Petrov, Monte M. Winslow, Katerina Politi

Cancer Res (2020) 80 (16_Supplement): 1094.

https://doi.org/10.1158/1538-7445.AM2020-1094

Published: 15 August 2020

View article titled, Abstract 1094: Genetic determinants of EGFR-driven lung cancer growth and therapeutic response in vivo

Journal Articles

Abstract A13: ASCL1 confers tolerance to tyrosine kinase inhibitors in EGFR mutant lung cancer

Bomiao Hu, Fernando J. de Miguel, Zongzhi Liu, Lok-Hei Chan, Mary Ann Melnick, Qin Yan, Don Nguyen, Rong Fan, Katerina Politi

Cancer Res (2020) 80 (11_Supplement): A13.

https://doi.org/10.1158/1538-7445.CAMODELS2020-A13

Published: 02 June 2020

View article titled, Abstract A13: ASCL1 confers tolerance to tyrosine kinase inhibitors in EGFR mutant lung cancer

Journal Articles

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Cancer Res (2020) 80 (10): 2017–2030.

https://doi.org/10.1158/0008-5472.CAN-19-3819

Published: 15 May 2020

View article titled, Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Includes: Supplementary data

Journal Articles

Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis

Emily Wingrove, Zongzhi Z. Liu, Don X. Nguyen, Anna Arnal-Estape, Kiran D. Patel, Mary-Ann Melnick, Katerina Politi, Manuel Valiente, Harriet M. Kluger, Veronica L. Chiang

Cancer Res (2019) 79 (13_Supplement): 4552.

https://doi.org/10.1158/1538-7445.AM2019-4552

Published: 01 July 2019

View article titled, Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis

Journal Articles

ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas

Xiaoling Song, Pang-Dian Fan, Amlak Bantikassegn, Udayan Guha, David W. Threadgill, Harold Varmus, Katerina Politi

Cancer Res (2015) 75 (6): 1035–1045.

https://doi.org/10.1158/0008-5472.CAN-13-1625

Published: 12 March 2015

View article titled, ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas

Includes: Supplementary data

Journal Articles

Abstract LB-309: Non-covalent wild-type-sparing inhibitors of EGFR T790M .

Ho-June Lee, Gabriele Schaefer, Tim Heffron, Shiva Malek, Mark Merchant, Robert L. Yauch, Valentina Pirazzoli, Katerina Politi, Jeff Settleman

Cancer Res (2013) 73 (8_Supplement): LB-309.

https://doi.org/10.1158/1538-7445.AM2013-LB-309

Published: 15 April 2013

View article titled, Abstract LB-309: Non-covalent wild-type-sparing inhibitors of EGFR T790M .

NARROW

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Abstract IA006: Leveraging the extreme selection induced by therapeutic bottlenecks to subvert resistance via identifying evolutionarily-informed targets for orthogonal immunotherapy

PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

Abstract 451: AICAR targets oncogenic signaling pathways of MUC1-CT

Abstract NG11: Autologous humanized PDX modeling for immuno-oncology recapitulates the human tumor microenvironment

Abstract 126: Extreme selection constrains ability of EGFR-driven lung adenocarcinoma to diversify in response to erlotinib therapy

Abstract 1172: Oncogenic context shapes the fitness landscape of tumor suppression

Abstract 1124: PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells

Abstract 1540: Accumulation of the long noncoding RNA Malat1 is a central driver and therapeutic target in metastatic lung cancer

Abstract 839: YES1 is a novel druggable oncogene in small cell lung cancer

Abstract 5848: Inhibition of the CRM1 nuclear export protein can treat mutant KRAS tumors through stabilizing the DLC1 tumor suppressor protein

Abstract 1572: Broad glutamine pathway inhibition by DRP-104 results in anti-tumor activity in hypermetabolic lung tumors resistant to PD-1 or osimertinib therapy

Abstract 2508: Targeting mutant KRAS tumors by inhibiting cytoplasmic EZH2, which directly methylates and destabilizes the DLC1 tumor suppressor protein

Abstract 1613: A hypoxia-driven transcriptional program characterizes acquired resistance to immune checkpoint inhibitors in lung cancer

Abstract 1094: Genetic determinants of EGFR-driven lung cancer growth and therapeutic response in vivo

Abstract A13: ASCL1 confers tolerance to tyrosine kinase inhibitors in EGFR mutant lung cancer

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis

ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas

Abstract LB-309: Non-covalent wild-type-sparing inhibitors of EGFR T790M .

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only